US Patent

US11851407 — Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL

Method of Use · Assigned to Johns Hopkins University · Expires 2037-06-09 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses methods and compositions for synthesizing and using the radiolabeled prostate-specific membrane antigen inhibitor [18F]DCFPyL.

USPTO Abstract

Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3130`	—
`U-3317`	—

Patent Metadata

Patent number: US11851407
Jurisdiction: US
Classification: Method of Use
Expires: 2037-06-09
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Johns Hopkins University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.